Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Cerenome will present interim data from the multidose ReSPECT-LMM study of REYOBIQ (rhenium Re186 obisbemeda) in a poster at the SNO Annual Meeting in Philadelphia on November 13, 2026. The interim poster covers safety, dosimetry, CSF tumor cell enumeration, and treatment-course data on the first ten patients; the company aims to advance into an FDA-aligned Phase 2 dose randomization study in 2027 in support of potential accelerated approval.
Key figures
- Drug Name
- REYOBIQ (rhenium Re186 obisbemeda)
- Phase Of Trial
- Phase 1 (multidose ReSPECT-LMM study)
- Conference
- SNO 31st Annual Meeting, November 12-15, 2026, Philadelphia
- Abstract code
- CTNI-40
- Patients in interim data
- 10
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.